Evidence map›Paper›PMID 38040540›Full record

ArticleClinical lung cancer2024

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.

Caressa Hui, Eleanor Brown, Samantha Wong, Millie Das, Heather Wakelee, Joel Neal, Kavitha Ramchandran, Nathaniel J Myall, Daniel Pham, Lei Xing and 9 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Caressa HuiDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Eleanor BrownDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Samantha WongDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Millie DasDepartment of Medical Oncology, Stanford University, Stanford, CA.
Heather WakeleeDepartment of Medical Oncology, Stanford University, Stanford, CA.
Joel NealDepartment of Medical Oncology, Stanford University, Stanford, CA.
Kavitha RamchandranDepartment of Medical Oncology, Stanford University, Stanford, CA.
Nathaniel J MyallDepartment of Medical Oncology, Stanford University, Stanford, CA.
Daniel PhamDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Lei XingDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Yong YangDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Nataliya KovalchukDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Ying YuanDepartment of Biostatistics, Stanford University, Stanford, CA.
Ying LuDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Stanford, CA.
Michael XiangDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA.
Alex ChinDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Maximilian DiehnDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Billy W LooDepartment of Radiation Oncology, Stanford University, Stanford, CA.
Lucas K VitzthumDepartment of Radiation Oncology, Stanford University, Stanford, CA. Electronic address: vitzthum@stanford.edu.

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
Translational Biology CoreP01CA257907 · NCI · STANFORD UNIVERSITY · PI Maximilian Diehn, Quynh-Thu Xuan Le · 2022 to 2026
$12.0M
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancerR01CA254179 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.1M
NCI NIH HHS P01 CA257907NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA254179
6 · The paper itself

Abstract

introductionPrior attempts to escalate radiation dose for non-small cell lung cancer (NSCLC) have not improved survival. Given the high risk for cardiopulmonary toxicity with treatment and heterogenous presentation of locally advanced NSCLC, it is unlikely that a single dose regimen is optimal for all patients. This phase I/II trial aims to evaluate a novel treatment approach where the level of accelerated hypofractionation is determined by the predicted toxicity from dose to organs at risk (OARs).

methodsPatients ≥ 18 years old with lung cancer planned for fractionated radiotherapy to the lung with concurrent chemotherapy will be eligible. Radiation therapy (RT) will be delivered to a total dose of 60 to 66 Gy in 30, 25, or 20 fractions depending on the ability to meet constraints to key organs at risk including the lungs, heart, and esophagus. The primary endpoint is high grade pulmonary, esophageal, or cardiac toxicity. A Bayesian optimized design is used to determine stopping boundaries and evaluate the primary endpoint.

conclusionPACER will evaluate the safety and feasibility of personalized accelerated chemoradiotherapy for lung cancer.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBayes TheoremChemoradiotherapyClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicHumansLungClinical trialDose escalationIsotoxic radiationPersonalized medicinePersonalized radiation

Identifiers

PMID38040540
PMCPMC11334968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.